{"id":"NCT02415127","sponsor":"Amgen","briefTitle":"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia","officialTitle":"Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06","primaryCompletion":"2016-11","completion":"2016-11","firstPosted":"2015-04-14","resultsPosted":"2017-12-08","lastUpdate":"2024-12-19"},"enrollment":92,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Friedreich's Ataxia"],"interventions":[{"type":"DRUG","name":"Interferon γ-1b","otherNames":["ACTIMMUNE®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Interferon γ-1b","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this phase 3 randomized, multi-center, double-blind, placebo-controlled study is to evaluate the efficacy and safety of ACTIMMUNE® (interferon-γ 1b) in the treatment of Friedreich's Ataxia (FA) and to evaluate the pharmacokinetic (PK) characteristics of ACTIMMUNE® in FA patients.","primaryOutcome":{"measure":"Change From Baseline to Week 26 in the Friedreich's Ataxia Rating Scale (FARS)-mNeuro Score","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Interferon γ-1b","deltaMin":-0.6,"sd":4.61},{"arm":"Placebo","deltaMin":-1,"sd":4.41}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5442"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":47},"commonTop":["Headache","Nausea","Pyrexia","Nasal congestion","Oropharyngeal pain"]}}